Abstract

IntroductionThe diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the “HCV care continuum”) have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD.Methods/designScientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis.DiscussionThrough this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD.Systematic review registrationPROSPERO CRD42016034113Electronic supplementary materialThe online version of this article (doi:10.1186/s13643-016-0293-6) contains supplementary material, which is available to authorized users.

Highlights

  • The diagnosis, management, and treatment for hepatitis C virus (HCV) infection have improved in recent years

  • Through this review, we hope to quantify the proportion of People who use drugs (PWUD) at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD

  • We will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD

Read more

Summary

Discussion

This systematic review and meta-analysis will critically assess the progression of PWUD through the steps in the HCV care continuum. In addition to identifying the proportions of PWUD/PWID progressing through care continuum steps, we will examine studies for the presence of covariates which, if reported and present, may be associated with progression through care continuum steps in an attempt to identify barriers to and facilitators of progression. This will help identify points where interventions are needed to improve individual and population-level progress through the care continuum and will help to elucidate modifiable barriers, facilitators, and predictors of progression through the care continuum, including those relevant at each step and those relevant to achieving SVR via HCV treatment. Abbreviations HCV, hepatitis C virus; PRECIS-2, Pragmatic Explanatory Continuum Indicator Summary-2; PRISMA-P, Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols; PWID, people who inject drugs; PWUD, people who use drugs; SVR, sustained virologic response

Introduction
Methods
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call